摘要
Introduction: Epidermal growth factor receptor (EGFR) is one of the most common driver gene mutations in non-small-cell lung cancer (NSCLC). EGFR-tyrosine kinase inhibitors (TKIs) monotherapy and EGFR-TKI combined with chemotherapy or anti-angiogenesis drugs have significantly prolonged the survival of patients with EGFR-mutant NSCLC. However, disease progression caused by acquired resistance to EGFR-TKIs is inevitable. And patients with EGFR exon 20ins showed limited efficacy to EGFR-TKIs. @@@ Areas covered: In this review, we initially evaluated the efficacy of existing treatments for EGFR-mutant NSCLC. Second, we reviewed the ongoing phase II and III clinical trials, provided the latest results, discussed the scientific rationale of these trials and the potential development issues. @@@ Expert opinion: The application of EGFR-TKIs has greatly changed the therapeutic strategies for advanced and resected NSCLC with EGFR mutations, and the 5-year overall survival (OS) rate for advanced NSCLC was close to 40%. The current research direction for the treatment of patients with EGFR mutations focuses on the following three aspects: uncommon EGFR mutation subtypes, brain metastases, and EGFR TKI-based combination therapy. Future studies on EGFR-mutant NSCLC therapy will focus on overcoming EGFR-TKI-related resistance, preventing drug resistance in advance, and developing bispecific antibody drugs.
学科与关键词
- Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancerLi, Yang-Si; Jie, Guang-Ling; Wu, Yi-Long*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231193726.
- Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancerZhou, Jia-Ying; Liu, Si-Yang; Wu, Yi-Long*Expert Opinion On Drug Safety, 2020, 19(5): 589-599.被引 12
- EGFR抑制剂治疗EGFR突变型晚期非小细胞肺癌的Meta分析张蓉; 陈薇雅; 甘洁民; 赵虎; 顾兆祥检验医学, 2013, (06): 506.
